Clinical Trials Browser

Has results × Leukemia, Lymphocytic, Chronic, B-Cell × daratumumab × Clear all

NCT04230304 2025-12-30

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Phase 2 Terminated

8 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell